报价延迟最少15分钟:2025/09/19 00:51 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
23.46 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.34/-1.98
|
|
企业价值
657.36M
|
| 资产负债 |
|
每股账面净值
15.70
|
| 现金流量 |
|
现金流量率
0.10
|
| 损益表 |
|
收益
332.07M
|
|
每股收益
6.62
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/19 00:51 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets. |
